The Effect of Silencing of UBE2C Gene on the Proliferation and Migration of Human Gastric Cancer AGS Cells
-
摘要:
目的 探讨UBE2C基因沉默对人胃癌AGS细胞增殖和迁移能力的影响。 方法 将用RNA 干扰技术构建的UBE2C-shRNA表达载体转染到293T细胞,用含有病毒颗粒的上清感染人胃癌AGS细胞,经puromycin筛选获得稳定表达的AGS细胞株。实验分为UBE2C表达沉默人胃癌AGS细胞组(干扰组)和对照组。采用qRT-PCR验证人胃癌AGS细胞中UBE2C的mRNA 表达水平,随后利用实时无标记细胞分析仪(RTCA)检测UBE2C沉默对人胃癌AGS细胞的增殖和迁移情况;同时应用CCK-8 细胞增殖检测试剂盒进一步印证UBE2C表达水平对人胃癌AGS细胞增殖能力影响。 结果 干扰组中UBE2C mRNA 表达 水平与对照组相比明显降低,AGS细胞增殖和迁移能力显著下降(P < 0.01)。 结论 靶向沉默UBE2C基因表达能抑制人胃癌AGS细胞恶性生物学行为。 Abstract:Objective To investigate the influence of the silence of UBE2C gene on the gastric cancer AGS cells proliferation and migration of human. Methods Using RNA interference technology, the expression vector of UBE2C silenced lentivirus was transfered into 293T cell line with packaging plasmids to produce the lentiviral particles. Lentivirus was used to infect human gastric cancer AGS cells, and the cells with stably expressing UBE2C were obtained by puromycin screening. The experiment was divided into the interference group and the interference control group. The expression levels of UBE2C mRNA in human gastric cancer AGS cells were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The capacity of AGS cell proliferation and migration was determined with real-time label free cell analyzer (RTCA). Meanwhile, Cell counting kit-8 (CCK-8) was used to further confirm the effect of UBE2C expression level on the proliferation of human gastric cancer AGS cells. Results Compared with the interference control group, UBE2C shRNA transfected human gastric cancer AGS cells significantly decreased the expression of UBE2C mRNA (P < 0.05); the cellular proliferation and migration ability were obviously decreased. Conclusion Targeted silencing of UBE2C gene expression can inhibit the malignant biological behavior of human gastric cancer AGS cells. -
Key words:
- UBE2C /
- human gastric cancer AGS cells /
- proliferation /
- Migration
-
表 1 引物信息
Table 1. Primer information
基因 引物序列5′→3′ UBE2C forward:ATCCATGGAGCAGCTGGAAC reverse:GGCAGCATGTGTGTTCAAGG GAPDH forward:GAGCCACATCGCTCAGACAC reverse:CATGTAGTTGAGGTCAATGAAGG -
[1] Etemadi A,Safiri S,Sepanlou S. G,et al. The global,regional,and national burden of stomach cancer in 195 countries,1990-2017:A systematic analysis for the Global Burden of Disease study 2017[J]. Lancet Gastroenterol Hepatol,2020,5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0 [2] 王静雷,杨一兵,耿云霞,等. 1990-2017年中国胃癌发病,患病及死亡状况趋势分析[J]. 中国慢性病预防与控制,2020,28(5):321-325. [3] A. Williamson,K. E. Wickliffe,B. G. Mellone,et al. Identification of a physiological E2 module for the human anaphase-promoting complex[J]. Proc. Natl. Acad. Sci. U. S. A,2009,106(43):18213-18218. doi: 10.1073/pnas.0907887106 [4] M. K. Summers,B. Pan,K. Mukhyala,et al. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC[J]. Mol. Cell,2008,31(4):544-556. doi: 10.1016/j.molcel.2008.07.014 [5] Townsley F M,Aristarkhov A,Beck S,et al. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase[J]. Proceedings of the National Academy of Sciences of the United States of America,1997,94(6):2362-2367. doi: 10.1073/pnas.94.6.2362 [6] Yanagida M. Basic mechanism of eukaryotic chromosome segregation. Philosophical[J]. Transactions Biological Sciences,2005,360(1455):609-621. doi: 10.1098/rstb.2004.1615 [7] Reddy S K,Rape M,Margansky W A,et al. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation[J]. Nature,2007,446(7138):921-925. doi: 10.1038/nature05734 [8] Okamoto Y,Ozaki T,Kou M,et al. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme[J]. Cancer Research,2003,63(14):4167-4173. [9] Guo J,Wu Y,Du J,et al. Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression[J]. Oncogenesis,2018,7(6):49-64. doi: 10.1038/s41389-018-0054-6 [10] Wang R,Song Y,Liu X,et al. UBE2C induces EMT through Wnt/βcatenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A[J]. International Journal of Oncology,2017,50(4):1116-1126. doi: 10.3892/ijo.2017.3880 [11] A Z J,B X Z,A L C,et al. UBE2C promotes the progression of head and neck squamous cell carcinoma[J]. Biochemical and Biophysical Research Communications,2020,523(2):389-397. doi: 10.1016/j.bbrc.2019.12.064 [12] Mo C H,Gao L,Zhu X F,et al. The clinicopathological significance of UBE2C in breast cancer:A study based on immunohistochemistry,microarray and RNA-sequencing data[J]. Cancer Cell International,2017,17(1):83-100. doi: 10.1186/s12935-017-0455-1 [13] 魏震,苌婉梅,郭小雨,等. UBE2C在结直肠癌中的研究现状与进展[J]. 现代肿瘤医学,2019,27(4):144-147.